BeiGene CMO Hematology Jane Huang resigns; consulting agreement through Nov 2022

BeOne Medicines Ltd.

Jane Huang, M.D., CMO Hematology, resigned effective April 3, 2022.
Consulting agreement runs from April 3 to November 14, 2022.
Unvested options/RSUs continue vesting until June 30, 2022; exercise period extended to 90 days after consulting ends.
No immediate replacement for CMO Hematology announced.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jane Huang

Chief Medical Officer, Hematology

ONC · BeOne Medicines Ltd.

Effective: 2022-04-03
Filed: March 3, 2022, 6:59 PM ET

On March 2, 2022, Jane Huang, M.D., Chief Medical Officer, Hematology of BeiGene, Ltd. (the “Company”), provided notice of her resignation from the Company effective April 3, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jane Huang resigned as Chief Medical Officer, Hematology at BeOne Medicines Ltd..

Action: resigned
Role: Chief Medical Officer, Hematology

Exact text from the filing

On March 2, 2022, Jane Huang, M.D., Chief Medical Officer, Hematology of BeiGene, Ltd. (the “Company”), provided notice of her resignation from the Company effective April 3, 2022.

View on SEC.gov

BeOne Medicines Ltd. filing history →

Source: SEC EDGAR

accession 0001651308-22-000038

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.